Increased Spontaneous Central Bleeding and Cognition Impairment in APP/PS1 Mice with Poorly Controlled Diabetes Mellitus

[1]  H. Ikeda,et al.  Cannabinoid functions in the amygdala contribute to conditioned fear memory in streptozotocin-induced diabetic mice: Interaction with glutamatergic functions , 2015, Experimental Neurology.

[2]  K. Stover,et al.  Analysis of motor function in 6-month-old male and female 3xTg-AD mice , 2015, Behavioural Brain Research.

[3]  Deepali Gupta,et al.  Ondansetron, a 5HT3 receptor antagonist reverses depression and anxiety-like behavior in streptozotocin-induced diabetic mice: possible implication of serotonergic system. , 2014, European journal of pharmacology.

[4]  M. Garcia-Alloza,et al.  Prediabetes-induced vascular alterations exacerbate central pathology in APPswe/PS1dE9 mice , 2014, Psychoneuroendocrinology.

[5]  Jian-qin Wang,et al.  Brain Aging and AD-Like Pathology in Streptozotocin-Induced Diabetic Rats , 2014, Journal of diabetes research.

[6]  Song Yu,et al.  Streptozotocin-induced diabetes increases amyloid plaque deposition in AD transgenic mice through modulating AGEs/RAGE/NF-κB pathway , 2014, The International journal of neuroscience.

[7]  A. Marette,et al.  INSULIN REVERSES THE HIGH FAT DIET-INDUCED INCREASE IN BRAIN Aβ AND IMPROVES MEMORY IN AN ANIMAL MODEL OF ALZHEIMER'S DISEASE , 2014, Alzheimer's & Dementia.

[8]  Geert Jan Biessels,et al.  Brain Changes Underlying Cognitive Dysfunction in Diabetes: What Can We Learn From MRI? , 2014, Diabetes.

[9]  A. Bretteville,et al.  Insulin dysfunction and Tau pathology , 2013, Front. Cell. Neurosci..

[10]  C. Hölscher,et al.  New animal models of Alzheimer’s disease that display insulin desensitization in the brain , 2013, Reviews in the neurosciences.

[11]  C. Rosano,et al.  Frontal gray matter atrophy in middle aged adults with type 1 diabetes is independent of cardiovascular risk factors and diabetes complications. , 2013, Journal of diabetes and its complications.

[12]  T. Spires-Jones,et al.  Differential central pathology and cognitive impairment in pre-diabetic and diabetic mice , 2013, Psychoneuroendocrinology.

[13]  E. Søfteland,et al.  Macrostructural brain changes in patients with longstanding type 1 diabetes mellitus - a cortical thickness analysis study. , 2013, Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association.

[14]  T. Spires-Jones,et al.  Rapid β-amyloid deposition and cognitive impairment after cholinergic denervation in APP/PS1 mice. , 2013, Journal of neuropathology and experimental neurology.

[15]  P. Maher,et al.  Diabetes exacerbates amyloid and neurovascular pathology in aging‐accelerated mice , 2012, Aging cell.

[16]  M. Ohno,et al.  Mechanisms Underlying Insulin Deficiency-Induced Acceleration of β-Amyloidosis in a Mouse Model of Alzheimer's Disease , 2012, PloS one.

[17]  L. Kappelle,et al.  Diabetes, hyperglycaemia, and acute ischaemic stroke , 2012, The Lancet Neurology.

[18]  T. Montine,et al.  Intranasal Insulin Therapy for Alzheimer Disease and Amnestic Mild Cognitive Impairment A Pilot Clinical Trial , 2011 .

[19]  C. Ayata,et al.  Cerebrovascular lesions induce transient β-amyloid deposition. , 2011, Brain : a journal of neurology.

[20]  U. Tuor,et al.  RETRACTED: Differential impact of diabetes and hypertension in the brain: Adverse effects in grey matter , 2011, Neurobiology of Disease.

[21]  Ke-xiang Zhao,et al.  Ghrelin-Attenuated Cognitive Dysfunction in Streptozotocin-induced Diabetic Rats , 2011, Alzheimer disease and associated disorders.

[22]  B. Hyman,et al.  Neuropathological alterations in Alzheimer disease. , 2011, Cold Spring Harbor perspectives in medicine.

[23]  Arturo Pujia,et al.  Possible implications of insulin resistance and glucose metabolism in Alzheimer’s disease pathogenesis , 2011, Journal of cellular and molecular medicine.

[24]  George Perry,et al.  Insulin-resistant brain state: The culprit in sporadic Alzheimer's disease? , 2011, Ageing Research Reviews.

[25]  Tao Wang,et al.  Insulin deficiency exacerbates cerebral amyloidosis and behavioral deficits in an Alzheimer transgenic mouse model , 2010, Molecular Neurodegeneration.

[26]  E. Masliah,et al.  Type 1 diabetes exaggerates features of Alzheimer's disease in APP transgenic mice , 2010, Experimental Neurology.

[27]  D. Consoli,et al.  Effects of insulinic therapy on cognitive impairment in patients with Alzheimer disease and Diabetes Mellitus type-2 , 2010, Journal of the Neurological Sciences.

[28]  Eva L Feldman,et al.  Increased tau phosphorylation and cleavage in mouse models of type 1 and type 2 diabetes. , 2009, Endocrinology.

[29]  A. Hofman,et al.  Insulin metabolism and the risk of Alzheimer's disease: The Rotterdam Study , 2009, Alzheimer's & Dementia.

[30]  Yaakov Stern,et al.  Contribution of vascular risk factors to the progression in Alzheimer disease. , 2009, Archives of neurology.

[31]  Suzanne Craft,et al.  The role of metabolic disorders in Alzheimer disease and vascular dementia: two roads converged. , 2009, Archives of neurology.

[32]  U. Tuor,et al.  Intranasal insulin prevents cognitive decline, cerebral atrophy and white matter changes in murine type I diabetic encephalopathy. , 2008, Brain : a journal of neurology.

[33]  J. Wands,et al.  Alzheimer's Disease is Type 3 Diabetes—Evidence Reviewed , 2008, Journal of diabetes science and technology.

[34]  W. Markesbery,et al.  AD brain pathology: Vascular origins? Results from the HAAS autopsy study , 2008, Neurobiology of Aging.

[35]  T. Brismar,et al.  Cognitive impairment correlates to low auditory event-related potential amplitudes in type 1 diabetes , 2008, Psychoneuroendocrinology.

[36]  R. Carare,et al.  Perivascular drainage of amyloid-beta peptides from the brain and its failure in cerebral amyloid angiopathy and Alzheimer's disease. , 2008, Brain pathology.

[37]  D. Holtzman,et al.  Rapid appearance and local toxicity of amyloid-β plaques in a mouse model of Alzheimer’s disease , 2008, Nature.

[38]  Elizabeth R Seaquist,et al.  Cognitive Dysfunction and Diabetes Mellitus , 2022 .

[39]  R. Carare,et al.  SYMPOSIUM: Clearance of Aβ from the Brain in Alzheimer's Disease: Perivascular Drainage of Amyloid‐β Peptides from the Brain and Its Failure in Cerebral Amyloid Angiopathy and Alzheimer's Disease , 2007 .

[40]  R. Mayeux,et al.  Metabolic syndrome and dementia risk in a multiethnic elderly cohort , 2007, Journal of the Neurological Sciences.

[41]  Brian J. Bacskai,et al.  Characterization of amyloid deposition in the APPswe/PS1dE9 mouse model of Alzheimer disease , 2006, Neurobiology of Disease.

[42]  A. Zmijewska,et al.  Tau Is Hyperphosphorylated at Multiple Sites in Mouse Brain In Vivo After Streptozotocin-Induced Insulin Deficiency , 2006, Diabetes.

[43]  D. Bennett,et al.  Diabetes and function in different cognitive systems in older individuals without dementia. , 2006, Diabetes care.

[44]  Joseph P Huston,et al.  Episodic-like memory in mice: simultaneous assessment of object, place and temporal order memory. , 2005, Brain research. Brain research protocols.

[45]  Joseph P. Huston,et al.  Integrated memory for objects, places, and temporal order: Evidence for episodic-like memory in mice , 2005, Neurobiology of Learning and Memory.

[46]  R. Mayeux,et al.  Hyperinsulinemia and risk of Alzheimer disease , 2004, Neurology.

[47]  L. Thal,et al.  Mild hypercholesterolemia is an early risk factor for the development of Alzheimer amyloid pathology , 2003, Neurology.

[48]  E. Northam,et al.  Neuropsychological profiles of children with type 1 diabetes 6 years after disease onset. , 2001, Diabetes care.

[49]  George Paxinos,et al.  The Mouse Brain in Stereotaxic Coordinates , 2001 .

[50]  A. Ott.  Risk of dementia: The Rotterdam Study , 1997 .

[51]  A. Hofman,et al.  Association of diabetes mellitus and dementia: The Rotterdam Study , 1996, Diabetologia.

[52]  Y. Liu,et al.  Impaired amyloid β-degrading enzymes in brain of streptozotocin-induced diabetic rats , 2011 .

[53]  M. Mattson,et al.  GLP-1 receptor stimulation reduces amyloid-beta peptide accumulation and cytotoxicity in cellular and animal models of Alzheimer's disease. , 2010, Journal of Alzheimer's disease : JAD.

[54]  G. Wilcock,et al.  The metabolic syndrome and Alzheimer disease. , 2007, Archives of neurology.

[55]  H. Soininen,et al.  Hypertension and Hypercholesterolaemia as Risk Factors for Alzheimer’s Disease , 2002, CNS drugs.

[56]  L. Molinari,et al.  Impaired intellectual development in children with Type I diabetes: association with HbA1 c, age at diagnosis and sex , 2002, Diabetologia.